AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $0.79

-0.09 (-10.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AGE News From Around the Web

Below are the latest news stories about AgeX Therapeutics Inc that investors may wish to consider to help them evaluate AGE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back to a new year, investor!

William White on InvestorPlace | January 3, 2022

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

ALAMEDA, Calif., December 14, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effe

Yahoo | December 14, 2021

AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif., November 30, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. ("ImStem"), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. I

Yahoo | November 30, 2021

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif., November 23, 2021--AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stock

Yahoo | November 23, 2021

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif., November 12, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021.

Yahoo | November 12, 2021

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif., August 13, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.

Yahoo | August 13, 2021

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

ALAMEDA, Calif. & PITTSBURGH, July 23, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was in

Yahoo | July 23, 2021

AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.

Yahoo | May 17, 2021

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

Yahoo | March 31, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5703 seconds.